U.S. markets open in 4 hours 32 minutes
  • S&P Futures

    4,216.25
    +6.25 (+0.15%)
     
  • Dow Futures

    33,337.00
    +77.00 (+0.23%)
     
  • Nasdaq Futures

    13,409.25
    +17.25 (+0.13%)
     
  • Russell 2000 Futures

    1,974.30
    +4.80 (+0.24%)
     
  • Crude Oil

    92.13
    +0.20 (+0.22%)
     
  • Gold

    1,802.20
    -11.50 (-0.63%)
     
  • Silver

    20.40
    -0.35 (-1.67%)
     
  • EUR/USD

    1.0342
    +0.0040 (+0.39%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • Vix

    20.04
    -1.73 (-7.95%)
     
  • GBP/USD

    1.2246
    +0.0028 (+0.23%)
     
  • USD/JPY

    132.5050
    -0.3680 (-0.28%)
     
  • BTC-USD

    24,485.42
    +1,361.18 (+5.89%)
     
  • CMC Crypto 200

    576.25
    +45.03 (+8.48%)
     
  • FTSE 100

    7,499.84
    -7.27 (-0.10%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path'

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The merger agreement between EW Partners and TherapeuticsMD Inc (NASDAQ: TXMDwas terminated, with EW Partners not acquiring the majority of shares to complete the tender offer successfully.

  • HC Wainwright said it is unclear what non-tendering shareholders hoped to accomplish.

  • The tender offer documents indicated that EW at times considered bids as high as $18/share, so perhaps investors not tendering hoped that EW would increase their bid.

  • After the unsuccessful tender and termination of the merger agreement, TherapeuticsMD reached an agreement with its creditors, in which the maturity date of the financing agreement was amended to July 24, 2022.

  • TXMD noted that it is considering filing for Chapter 11 bankruptcy or could also try to restart the sale process,

  • HC Wainwright's price target and rating are under review as the company seeks to identify a path forward.

  • TXMD is not currently generating a profit, and its liquidity could negatively affect the company's ability to sell Annovera, its largest commercial product.

  • Price Action: TXMD shares are up 3.13% at $5.45 during the market session on the last check Friday.

Latest Ratings for TXMD

Date

Firm

Action

From

To

Mar 2022

HC Wainwright & Co.

Maintains

Buy

Nov 2021

HC Wainwright & Co.

Maintains

Buy

Aug 2020

Jefferies

Downgrades

Hold

Underperform

View More Analyst Ratings for TXMD

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.